Beam Therapeutics Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Beam Therapeutics Inc. (BEAM) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $56.02 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-24
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $56.02M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $66.31M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $78.60M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $88.95M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $56.02M 10-K · filed 2026-02-24 |
| 2024-12-31 | $66.31M 10-K · filed 2025-02-25 |
| 2023-12-31 | $78.60M 10-K · filed 2024-02-27 |
| 2022-12-31 | $88.95M 10-K · filed 2023-02-28 |
| 2022-09-30 | $90.29M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $96.29M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $59.97M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $62.25M 10-K · filed 2022-02-28 |
| 2021-09-30 | $67.31M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $73.58M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $81.51M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $69.11M 10-K · filed 2021-03-15 |
| 2020-09-30 | $10.33M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $10.99M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $10.76M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |